Despite these early successes, four subsequent Phase 2 studies of Zantrene in 100 melanoma patients used much longer dosing intervals of once every three or 4 weeks and did not achieve the same levels of clinical response, possibly due to limited, transient inhibition of FTO. 8-11. Seventeen patients (1/16, 2/16, 0/17, 14/51) achieved disease stabilization, but no further complete responses were observed
Ann: Zantrene highly effective in Melanoma preclinical study, page-35
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
0.008(0.49%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.57 | $1.54 | $22.94K | 14.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 20661 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.54 | 1500 | 1 |
View Market Depth
| Last trade - 12.20pm 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |